The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/88461

Please be advised that this information was generated on 2018-11-14 and may be subject to change.
Gout is an acute inflammatory arthritis with the potency to fully destroy the integrity of the joint leading to severe disability. Besides joint destruction, gout is often associated with an accelerated atherosclerosis culminating in an increased risk of cardiovascular disease. The current existing therapy modalities allow an efficient treatment that not only controls local inflammation but might also have an effect on the generalised features that surround this condition. Here we discuss the modes of clinical appearance, how we are nowadays supposed to treat gout and the current knowledge about the pathogenesis of this clinical syndrome.

**KEYWORDS**
Gout, cardiovascular risk, immunology

**INTRODUCTION**

Gout is an acute inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals intra-articularly. Patients experience acute severe pain that often forces them to seek medical care. Besides the acute presentation patients can present with tophi, which can even precede joint involvement. With an estimated prevalence of 1 to 2% in adults in developed countries, this therefore accounts for a substantial burden of work-related and medical costs. In the elderly (age >65 years) the incidence even increases to 8% for men and 3% for women. The male:female ratio ranges from 7:1 to 9:1. Most patients with gout (≥90%) are diagnosed and treated by general practitioners in primary care. Besides the involvement of joints, gout is often accompanied by other symptoms of hyperuricaemia such as the formation of tophi in numerous tissues. The prevalence of hyperuricaemia is 10 to 20% in the Western population and a substantial number of these patients stay asymptomatic during life. Only a minority of individuals with elevated serum urate levels develop gout (incidence rate less than 50/1000/year for ≥0.54 mmol/l; 5/1000/year for 0.42 to 0.54 mmol/l; 1/1000/year <0.42 mmol/l). Compared with other mammals humans have high uric acid levels due to two deletions in the promotor site of uricase. This causes the uric acid plasma levels to be around 300 μM, a level at which a small increment could cause supersaturation and crystal formation. There is a strong association between hyperuricaemia and the metabolic syndrome (the constellation of insulin resistance, hypertension, obesity and dyslipidaemia), potentially explained by dietary and lifestyle changes. This is profoundly demonstrated by the prototypic gouty patient being an obese, middle-aged man with a Burgundian lifestyle and a medical history of hypertension, kidney disease, diabetes mellitus and signs of vascular problems such as coronary artery disease, heart failure and stroke. But as previously reported gout can also present in elderly patients without known risk factors, even presenting only with tophi. In gouty arthritis the formation of MSU crystals into the joint promotes acute inflammation. These crystals have the capacity to induce the release of various inflammatory mediators in inflammatory cells. In the past ten years research on the role of the innate immune system in the pathogenesis of gout has extended rapidly. As our knowledge on the inflammatory processes accompanying atherosclerosis also increases it is tempting to discuss the development of cardiovascular diseases in gout patients via immunological perturbations.

In daily clinical practice the diagnosis of gout can be made easily and with a high certainty using the gold standard. The gold standard is the presence of MSU crystals in the
synovial fluid or a tophus, and therefore a puncture of a joint or tophus should always be performed. Recently it was shown that the American College of Rheumatology (ACR) criteria from 1977 have a limited validity, at least in primary care.17 We describe two patients who visited the emergency department because of severe gouty arthritis. The aim of this study is to review the literature concerning cardiovascular risks and pathogenic aspects of gout. In addition, we provide an overview on the clinical assessment and therapeutic armamentarium.

CASES

PATIENT A

A 75-year-old male presented at the emergency unit with a five-day history of severe pain and swelling of digit IV of the left foot. The general practitioner had already started colchicine 0.5 mg ten times daily. This led to complaints of vomiting and diarrhoea and eventually to a visit to the emergency department. His medical history was characterised by major cardiovascular complications consisting of a myocardial infarction in 1986 followed by a large aneurysm of the left ventricle and mild mitral valve insufficiency (diagnosed in 1993). A second myocardial infarction followed in 1994. In 2002 an acute coronary syndrome led to dilation and placement of a stent in the right coronary artery. In 2008 diagnostic procedures were undertaken because of progressive dyspnoea and cardiac ultrasound revealed a markedly diminished function of the left ventricle (ejection fraction 25 to 30%), insufficiency of the mitral and aortal valves and suspicion of pulmonary arterial hypertension. Based on these observations, an intracardiac defibrillator was inserted. Besides his cardiac history, hypothyroidism, peptic ulcers and gout had been present for eight years. Physical examination revealed a swelling of digit IV of his left foot with a tophus that showed signs of infection and distinct tophi in the olecranal bursa bilaterally (figures 1A and B). Apart from the common signs of dehydration, no other signs of illness were present. Laboratory analysis was normal (no acute phase response present) except for the increased serum uric acid of 0.92 mmol/l (reference 0.20 to 0.40 mmol/l) and creatinine 306 μmol/l (reference 60 to 110 μmol/l) levels. Radiographic evaluation of the left foot revealed a complete resorption of the distal phalanx digit IV (figure 1C); no other abnormalities were present. Since the patient was dehydrated because of diarrhoea due to the high dose of colchicine, 120 mg, the arthritis was treated with triamcinolone acetonide intramuscularly and not with an NSAID, and the dosage of colchicine was lowered to 0.5 mg once daily. One week later the patient attended our outpatient clinic. He was fully recovered and showed no signs of dehydration and pain in the toe. Although exceptional, since the gouty disease in this patient was very local and led to a high risk for an infectious complication, we discussed an amputation of digit IV with the patient. Not surprisingly, the toe had given many complaints over the past three years and the patient agreed to this approach. Two weeks after presentation at the emergency ward the toe was amputated. As expected, the histological analysis of the amputated digit showed clear MSU crystals and no evidence for infection. Two weeks after surgery the patient visited our outpatient clinic with complete healing of the site of amputation (figure 1D). Since the medical history of the patient included more than three gout attacks per year we started allopurinol 200 mg once daily under the cover of corticosteroids. This led to the normalisation of

Figure 1. Patient A

A) Digit IV of the left foot with an ulcerating wound with a tophus present proximally, B) lateral and frontal view of the left olecranal bursa with multiple subcutaneous nodules (tophi) present. C) X-ray of the left foot showing complete disappearance of the bone due to the gouty inflammation and D) left foot after amputation of digit IV. The patient provided consent to publish the photos.
the serum urate below the level of 0.36 mmol/l, which is the current target value of the European League against Rheumatism (EULAR), and absence of gout attacks after two years of follow-up.

**PATIENT B**

A 93-year-old female came to the rheumatology clinic with pain and swelling in both hands and a probable 12-year history of gout. She had not received any treatment for her gout so far. Her only relevant medical history was primary hypertension. Physical examination showed multiple swollen proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints in both hands with an extensive amount of tophi (figures 2A and B). Inspection of digit IV of the right hand revealed a fistulating tophus (figure 2C). Laboratory analysis showed a serum uric acid of 0.46 mmol/l (reference 0.20 to 0.40 mmol/l) and creatinine 69 μmol/l (reference 60 to 110 μmol/l) and an acute phase reaction: ESR 34 mm/h and CRP 45 mg/l. To analyse the extent of joint damage conventional radiological examination was performed which revealed extensive destruction of multiple PIP and DIP joints (known as ‘punched out’ lesions). As treatment, clindamycin 200 mg was given three times daily (for two weeks) and methylprednisolone (120 mg) was administered once intramuscularly. Two weeks later all the signs of inflammation had completely resolved. At that moment allopurinol 200 mg once daily was added, which led to the normalisation of the serum urate level (<0.36 mmol/l). After two years of follow-up, the patient had twice suffered from a gout attack which quickly recovered (within two days) by the addition of colchicine three times daily 0.5 mg for one week.

**GOUT AND CARDIOVASCULAR MORBIDITY AND MORTALITY: MORE THAN A LOCAL DISEASE?**

While an association between gout and hypertension, other cardiovascular diseases and kidney diseases has been observed since the late 19th century, renewed interest started from the late 20th century through defining of new top priorities in medicine, such as reduction of cardiovascular morbidity and mortality. To date, several studies underscore that gout is an independent risk factor for cardiovascular disease (table 1) .

In the prospective Framingham study ‘clinical’ gout was associated with an increased risk of coronary heart disease. Abbott et al. found an excess risk of 60% for coronary heart disease (CHD) among subjects with gout compared with those who did not have clinical gout. The Meharry-Hopkins study showed contradictory results, the pooled risk-adjusted relative risk (RR) for cardiovascular disease was 0.59 (95% CI 0.24 to 1.46). However, this study was underpowered with just three events in the 31 subjects of the Meharry cohort and four events in 62 subjects of Johns Hopkins Precursors cohort. A Dutch study based on data from general practitioners demonstrated that 270 patients with a first episode of gout had a statistically higher prevalence of one or more signs of cardiovascular disease (35 vs 26%) compared with 522 healthy counterparts. In follow-up of this study, 170 gout patients without cardiovascular disease were compared with 340 control patients from the general practitioners’ database. Data revealed a statistically higher prevalence of hypertension (39 vs 14%), hypercholesterolaemia (8 vs 4%), diabetes mellitus (5 vs 1%) and obesity (52 vs 27%) among the 170 gout patients.

The prospective Multiple Risk Factor Intervention Trial (MRFIT) was a randomised clinical trial designed to examine the efficacy of coronary risk reduction of adverse coronary events. During the six-year intervention phase gout was associated with an increased risk of nonfatal acute myocardial infarction, odds ratio 1.26 (95% CI 1.14 to 1.4). In 2008, Krishnan et al. reported a 17-year follow-up study of the men in the MRFIT cohort who did not have CHD during the six-year intervention phase. The hazard ratio (HR) for CHD mortality for gout vs non-gout was 1.35 (95% CI 1.06 to 1.72).
Recently, a large Taiwanese study reported about the relationship between clinical gout and electrocardiographic evidence Q-wave myocardial infarction using the Ho-Ping Gout database of 22,572 established gout patients according to the Wallace criteria. In addition to this, Chen et al. demonstrated that gout was associated with Q-wave myocardial infarction. The prospective Health Professional Follow-up Study investigated the relation between history of gout and the risk of death and myocardial infarction among 51,297 men. During the 12-year follow-up period, Choi et al. found RRs of 1.38 (95% CI 1.15 to 1.66) for cardiovascular-related death and 1.55 (95% CI 1.24 to 1.93) for cardiovascular-related death in males with gout. Cohen et al. examined the association of gout and mortality among patients receiving dialysis therapy in the United States Renal Data System. In this study, gout was independently associated with CVD mortality with an HR of 1.47 (95% CI 1.26 to 1.66). However, this national registry did not contain information on other potential risk factors for mortality such as malnutrition, infection and social circumstances. The most recent study to date by Kuo et al. further substantiates the relationship between cardiovascular disease and gout using a cohort of 61,527 individuals and a follow-up period of seven years. Together, these prospective reports strongly suggest that men with gout, adjusted for various cardiovascular risk factors, are associated with increased cardiovascular disease risk, especially coronary heart disease mortality. Therefore aggressive management of cardiovascular risk factors in men with gout is warranted.

## Gout and Cardiovascular Morbidity and Mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Design</th>
<th>Follow-up (years)</th>
<th>Outcomes</th>
<th>Patients (total gout n)</th>
<th>Adjusted effect size (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott19</td>
<td>Framingham cohort</td>
<td>Cohort</td>
<td>12</td>
<td>CHD</td>
<td>37 (94)</td>
<td>1.60 (1.10-2.30)</td>
</tr>
<tr>
<td>Gelber20</td>
<td>Meharry-Hopkins cohort</td>
<td>Cohort</td>
<td>10</td>
<td>CHD</td>
<td>7 (93)</td>
<td>0.59 (0.24-1.46)</td>
</tr>
<tr>
<td>Janssens21</td>
<td>Continuous Morbidity Registration</td>
<td>Case-control</td>
<td>11</td>
<td>CVD</td>
<td>44 (70)</td>
<td>(0.65-1.47)</td>
</tr>
<tr>
<td>Krishnan22</td>
<td>Multiple risk factor</td>
<td>Cohort</td>
<td>6.5</td>
<td>Fatal MIs</td>
<td>22 (112)</td>
<td>0.96 (0.66-1.44)</td>
</tr>
<tr>
<td></td>
<td>Intervention trial</td>
<td></td>
<td></td>
<td>All MIs</td>
<td>118 (1123)</td>
<td>1.26 (1.14-1.40)</td>
</tr>
<tr>
<td>Krishnan23</td>
<td>Multiple risk factor</td>
<td>Cohort</td>
<td>17</td>
<td>Fatal MIs</td>
<td>36 (655)</td>
<td>1.35 (1.04-1.73)</td>
</tr>
<tr>
<td></td>
<td>Intervention trial</td>
<td></td>
<td></td>
<td>CHD mortality</td>
<td>78 (655)</td>
<td>1.35 (1.06-1.72)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CVD mortality</td>
<td>110 (655)</td>
<td>1.21 (0.99-1.49)</td>
</tr>
<tr>
<td>Chen25</td>
<td>Ho-Ping Gout Cohort</td>
<td>Cross-sectional</td>
<td>NA</td>
<td>Q-wave MIs</td>
<td>393 (2,257)</td>
<td>1.18 (1.02-1.38)</td>
</tr>
<tr>
<td>Choi26</td>
<td>Health Professionals Follow-up</td>
<td>Cohort</td>
<td>12</td>
<td>All-cause mortality</td>
<td>645 (2773)</td>
<td>1.28 (1.13-1.41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CHD mortality</td>
<td>238 (2773)</td>
<td>1.55 (1.24-1.93)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CVD mortality</td>
<td>304 (2773)</td>
<td>1.38 (1.15-1.66)</td>
</tr>
<tr>
<td>Cohen27</td>
<td>US Renal Data System dialysis</td>
<td>Cohort</td>
<td>5</td>
<td>All-cause mortality</td>
<td><em>(24,415)</em></td>
<td><em>(1.49-1.53)</em></td>
</tr>
<tr>
<td></td>
<td>patients</td>
<td></td>
<td></td>
<td>CVD mortality</td>
<td><em>(24,415)</em></td>
<td><em>(1.47-1.59)</em></td>
</tr>
<tr>
<td>Kuo28</td>
<td>Health Screening Program Chang Gung Memorial Hospital</td>
<td>Cohort</td>
<td>6</td>
<td>All-cause mortality</td>
<td><em>(131)</em></td>
<td>1.46 (1.12-1.91)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CVD mortality</td>
<td><em>(131)</em></td>
<td>1.97 (1.08-3.59)</td>
</tr>
</tbody>
</table>

*Numbers of outcome not reported.
CHD = coronary heart disease; CVD = cardiovascular disease; MIs = myocardial infarctions.
MSU crystals are potentially recognised by immune cells through Toll-like receptor 2 (and probably TLR4) and FcγRIIIB/CD16 subsequently leading to NF-kappaB activation and downstream signalling culminating in the production of proinflammatory cytokines such as interleukin-6, tumour necrosis factor α, interleukin-1β and interleukin-8 (IL-8). Actually, the stimulating capacity of MSU crystals to activate monocytes/macrophages to produce interleukin-1β (IL-1β) was already recognised 20 years ago but to date controversy remains about the precise mechanisms through which urate crystals drive inflammation. Recent studies have led to significant advances in the understanding of the basic biology of crystal-mediated inflammation. Uric acid has been identified as a danger signal that triggers a cytosolic sensor, the inflammasome, a signalling platform that is required for the activation of interleukin-1, a cytokine that is critical to the initiation of acute inflammation in gout (reviewed in Martinon, 2010). Interestingly, several studies have now suggested an effective treatment with IL1b inhibitors; however, these observations need confirmation in RCTs. Currently a study with canakinumab, an IL1b inhibitor, is underway. Another interesting finding recently published is the capacity of monocytes and/or the inflammatory environment in a gout-prone individual to prime neutrophils to produce increased levels of superoxide in response to MSU stimulation.

Intriguingly, the natural course of a gout attack is to spontaneously resolve in seven to ten days. Clearance of MSU by differentiated macrophages results in a decrease of leucocyte and endothelial activation with the end result that the inflammatory response fades away. Further in vitro research showed that in vitro generated macrophages failed to secrete cytokines in response to MSU. It is therefore interesting to hypothesise that the time to resolve a gout attack is directly correlated with the time a monocyte needs to become a fully differentiated macrophage in vitro. Further research is needed though to confirm this hypothesis. On the other hand in chronic gout low-grade synovitis persists even during remissions of acute flares. The ongoing inflammation causes joint damage through chondrocyte activation and the following matrix metalloproteinase production. Furthermore, MSU is able to reduce the anabolic effects of osteoblasts, also contributing to irreversible joint damage. These series of events could possibly explain the inflammatory circuitry that leads to joint destruction when inflammation is not controlled (figure 3). Next to irreversible joint damage the increased cardiovascular risk in patients with gout is

---

**Figure 3. Schematic overview of the pathogenesis of gout**

| Mononuclear cells are stimulated by MSU containing crystals, which subsequently activates a cascade of events where immunomodulatory mediators are produced resulting in the chemotraction and activation of other inflammatory cell subsets. After the initiating event, professional antigen presenting cells induce apoptosis of neighbouring inflammatory cells and secrete mediators that silence the immune response. |
Current Insights into the Management of Gout

Following the clear evidence of the destructive effects of gout on the joints and the cardiovascular system a clinician facing a patient with gout should be triggered to start treatment for these aspects of this disease. The EULAR evidence-based recommendations for gout is a European combined effort to develop key recommendations concerning diagnosis and management of gout. A total of 22 key recommendations were generated through six Delphi rounds. Table 2 presents a selection of the most important key recommendations for management of gout. In the short term, the treatment goal is to relieve symptoms as quickly as possible. First, activation of Toll-like receptors (TLRs) can block the induction of liver X receptor (LXR) target genes of the lipid metabolism. As activation of LXR and PPAR gamma can potentially prevent the development of atherosclerosis, an interaction between LXR and MSU induced TLR activation could explain the association with the uncontrolled rate of atherosclerosis in patients with gout. Second, two studies in rats, using dietary adjustments to induce hyperuricaemia, have shown that increased uric acid caused nephropathy resulting in increased renin levels and hypertension. Whether this mechanism can be translated to humans is a matter of debate and warrants further investigation. In addition, the contribution of chronic inflammation, oxidative stress and endothelial dysfunction to the development of cardiovascular disease in gout patients needs further attention as these processes intriguingly play a role in both diseases.

Table 2. Modified recommendations for management of gout

1. Optimal treatment of gout requires both nonpharmacological and pharmacological modalities and should be tailored according to:
   (a) Specific risk factors for gout such as elevated serum uric acid, previous attacks and radiographic signs
   (b) Clinical phase (acute/recurrent, chronic tophaceous gout)
   (c) General risk factors (age, sex, obesity, alcohol consumption, urate raising drugs, drug interactions and comorbidity)

2. NSAID and/or prednisolone are first-line agents for systemic treatment of acute attacks. Low-dose colchicine is an alternative.

3. Intra-articular aspiration and injection of a long-acting steroid is an effective and safe treatment for an acute attack.

4. Urate-lowering therapy is indicated in patients with recurrent acute attacks, arthropathy, tophi or radiographic changes of gout. The therapeutic goal of urate-lowering therapy is achieved by maintaining the serum uric below the saturation point of monosodium urate (<360μmol).

5. Allopurinol is an appropriate long-term urate-lowering drug; it should be started at a low dose (for example, 100 mg daily) and increased by 100 mg every 2-4 weeks if required; the dose must be adjusted in patients with renal impairment; if allopurinol toxicity occurs, options include other xanthine oxidase inhibitors, an uricosuric agent (benzbromarone) or allopurinol desensitisation (the latter only in cases of mild rash).

6. Prophylaxis against acute attacks during the first months of urate-lowering therapy can be achieved by colchicine (0.5-1 mg daily) and/or an NSAID.

7. When gout is associated with diuretic therapy, stop the diuretic if possible: for hypertension and hyperlipidaemia consider use of losartan and fenofibrate, respectively (both have modest uricosuric effects).

8. Associated comorbidity and cardiovascular risk factors such as hyperlipidaemia, hypertension, hyperglycaemia, obesity and smoking should be addressed as an important part of the management of gout.

Side effects which are severe enough to stop treatment in 5% of the cases. If there is intolerance against allopurinol an alternative approach is the use of an uricosuric drug; in the Netherlands benzbromarone as the only drug regularly available. In a recent randomised controlled trial the efficacy of benzbromarone 100 to 200 mg daily was equal to 300 to 600 mg allopurinol. Recently, a novel drug for the treatment of gout was introduced: febuxostat (Adenuric®). Febuxostat is a novel non-purine xanthine oxidase inhibitor. Urate levels of lower than 0.36 mmol/l were reached in 48 to 53% with daily use of 80 mg febuxostat and in 62 to 65% in the case of 120 mg febuxostat daily vs 56 to 62% and 85 to 93% with the use of 300 mg and 600 mg of allopurinol daily. Currently, there is a large debate about the effects that these treatments could have on cardiovascular risk. Aside from this urate-lowering therapy traditional cardiovascular risk factors such as hyperlipidaemia, hypertension, obesity and smoking should be addressed according to national cardiovascular risk management guidelines. Although clear trends are present.
that suggest that gout/hyperuricaemia is associated with an increased risk for premature death due to cardiovascular diseases, the final answer needs to come from clinical intervention studies that still need to be performed.

**CONCLUSION**

The cases discussed in this report clearly illustrate the severity of gout and demonstrate that even today, gout is not always recognised and treated as it should be. Nowadays, gout can be treated very effectively with the currently available therapeutic armamentarium. So far, prospective studies supported by evidence from basal immunology studies clearly show that gout is an independent risk factor for CVD. In the coming years the precise interplay of inflammatory mediators mediating the arthritic symptoms and the potential connection with an increased cardiovascular disease profile is to be expected. For now, correct and proactive management of gout taking into account the present risk factors for the development of cardiovascular disease should have a place in the treatment of every patient with this clinical syndrome.

**REFERENCES**


